Papers
6
Total Citations
196
H-Index
4
About
Mesut Remzi is a leading urologic surgeon whose research has significantly advanced the field of minimally invasive oncology. His work centers on optimizing surgical outcomes for kidney and prostate cancers, with a particular focus on comparing emerging technologies against established gold standards. Remzi’s most impactful contribution is a landmark systematic review and meta-analysis (105 citations) that rigorously compared laparoscopic cryoablation to laparoscopic partial nephrectomy for small renal tumors, providing crucial evidence for treatment selection. He has also been a pioneer in improving surgical safety, demonstrating that FloSeal hemostatic matrix can dramatically reduce lymphocele incidence after pelvic lymphadenectomy in robotic prostatectomy (55 citations). More recently, Remzi has contributed to the evidence base for robot-assisted partial nephrectomy, publishing a mid-term oncologic outcomes review (22 citations) that reinforces its role in renal mass management. His expertise extends to focal therapy for prostate cancer and, during the COVID-19 pandemic, he conducted a scoping review on intraoperative aerosol viral transmission in minimally invasive surgery, directly influencing clinical guidelines. Through his methodical, evidence-driven approach, Remzi has helped shape modern urologic practice, balancing innovation with proven patient safety.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4Focal therapy of prostate cancer9 citations · 2018
- 5
- 6Robotic Surgery Is Unnecessary for Adrenalectomy2 citations · 2015